These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 35933914)
1. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914 [TBL] [Abstract][Full Text] [Related]
2. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient. Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931 [TBL] [Abstract][Full Text] [Related]
3. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979 [TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib. Guo W; Liang J; Zhang D; Huang X; Lv Y Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356 [TBL] [Abstract][Full Text] [Related]
5. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Zhang SS; Nagasaka M; Zhu VW; Ou SI Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504 [TBL] [Abstract][Full Text] [Related]
6. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613 [TBL] [Abstract][Full Text] [Related]
7. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158 [TBL] [Abstract][Full Text] [Related]
8. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review. Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052 [TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. de Figueiredo-Pontes LL; Wong DW; Tin VP; Chung LP; Yasuda H; Yamaguchi N; Nakayama S; Jänne PA; Wong MP; Kobayashi SS; Costa DB J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423 [TBL] [Abstract][Full Text] [Related]
10. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. Elshatlawy M; Sampson J; Clarke K; Bayliss R Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843 [TBL] [Abstract][Full Text] [Related]
11. Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo. Yokota E; Iwai M; Ishida Y; Yukawa T; Matsubara M; Naomoto Y; Fujiwara H; Monobe Y; Haisa M; Takigawa N; Fukazawa T; Yamatsuji T Hum Cell; 2024 Jul; 37(4):1132-1140. PubMed ID: 38829559 [TBL] [Abstract][Full Text] [Related]
12. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer. Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576 [TBL] [Abstract][Full Text] [Related]
13. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177 [TBL] [Abstract][Full Text] [Related]
14. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. Liu D; Xu X; Wen J; Zhang C; Fan M Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065 [TBL] [Abstract][Full Text] [Related]
15. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via Chuang TP; Lai WY; Gabre JL; Lind DE; Umapathy G; Bokhari AA; Bergman B; Kristenson L; Thorén FB; Le A; Doebele RC; Van den Eynden J; Palmer RH; Hallberg B Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2216479120. PubMed ID: 36791109 [TBL] [Abstract][Full Text] [Related]
16. ALK inhibitors in the treatment of advanced NSCLC. Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927 [TBL] [Abstract][Full Text] [Related]
18. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. Miyanaga A; Shimizu K; Noro R; Seike M; Kitamura K; Kosaihira S; Minegishi Y; Shukuya T; Yoshimura A; Kawamoto M; Tsuchiya S; Hagiwara K; Soda M; Takeuchi K; Yamamoto N; Mano H; Ishikawa Y; Gemma A BMC Cancer; 2013 May; 13():262. PubMed ID: 23714228 [TBL] [Abstract][Full Text] [Related]
19. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK. Liu L; Hou F; Liu Y; Li W; Zhang H J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318 [TBL] [Abstract][Full Text] [Related]
20. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]